What were the key takeaways from Kymera Therapeutics’s earnings call?

What were the key takeaways from Kymera Therapeutics's earnings call?

What is Kymera Therapeutics's gross profit margin?

Did Kymera Therapeutics beat or miss consensus estimates last quarter?

What factors drove the changes in Kymera Therapeutics's revenue and profit?

What is the revenue and EPS growth rate for Kymera Therapeutics year over year?

What guidance did Kymera Therapeutics's management provide for the next earnings period?

What is the market's earnings forecast for Kymera Therapeutics next quarter?

- **Breakthrough STAT6 Program**: Phase IIb AD trial enrollment on track for mid-2027 data; asthma trial dosing begins Q1 2026.
- **$1.6B Cash Runway**: Supports Phase IIb trials and pipeline expansion into 2029.
- **IRF5 First-in-Human Study**: Initiated with target of 90% IRF5 knockdown, positioning for lupus proof-of-concept.
- **Strategic Collaborations**: $750M potential from Gilead CDK2 program and $1B from Sanofi IRAK4 program.

**【CEO Summary Section】**
- **2025 Milestones**: Achieved significant progress in STAT6 Degrader Program (KT-621), including Phase I healthy volunteer and Phase Ib AD studies. Launched Phase IIb trials in AD and asthma. Raised $1 billion, extending cash runway to 2029.
- **Market Opportunity**: Targeting 50 million moderate-to-severe Type 2 disease patients in major markets, with only 2 million treated by advanced therapies. KT-621 aims to address unmet need with oral, biologics-like efficacy.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Collaboration revenue $2.9M (Gilead partnership). Total cash balance $1.6B, supporting Phase IIb trials and pipeline expansion.
- **Pipeline Milestones**: Potential $750M from Gilead CDK2 program and $1B from Sanofi IRAK4 program. Upcoming milestones include Sanofi Phase I dosing and Gilead option exercise.

**【Q&A Highlights】**
- **KT-621 Development**: Phase IIb AD trial enrollment on track for mid-2027 data. Asthma trial dosing began in Q1 2026, with late-2027 readout. No interim analyses planned to preserve study integrity.
- **IRF5 Program**: Phase I healthy volunteer study initiated post-FDA clearance. Targeting 90% IRF5 knockdown in blood. Lupus patient proof-of-concept study expected post-Phase I data.
- **Competitive Landscape**: STAT6 degradation uniquely targets IL-4/13 pathway, with preclinical activity matching or exceeding biologics. IRF5's genetic validation and safety profile differentiate it from other autoimmune therapies.
- **Enrollment Dynamics**: Strong investigator and patient interest in oral, biologics-like options. Ex-U.S. sites dominate AD trial to access untreated severe patients.

Kymera Therapeutics, Inc. (KYMR) Q4 2025 Earnings Call Transcript

- **KT-621 Milestone Progress**: Phase Ib AD trial fully enrolled; Phase IIb AD and asthma trials initiated. 
- **Financial Strength**: $978M cash runway, with $2.8M Q3 revenue from Gilead. 
- **Pipeline Expansion**: IRF5 program advancing to clinic; oncology partnership with Gilead for CDK2 program. 
- **Efficacy Expectations**: KT-621 targeting dupilumab-like TARC reduction (70-80%) in AD, with Phase Ib data due in December.

**【CEO Summary Section】**
- Kymera achieved significant progress in 2025, including advancing KT-621 (STAT6 degrader) into Phase Ib trials for atopic dermatitis (AD) and initiating Phase IIb trials in AD and asthma. 
- KT-621 demonstrated robust STAT6 degradation in healthy volunteers, with potential for biologics-like efficacy in oral form. 
- Expanded pipeline includes IRF5 degrader (KT-579) with preclinical data showing efficacy in lupus and rheumatoid arthritis, and a new oncology partnership with Gilead for CDK2 program.

**【CFO Financial Commentary】**
- Q3 2025 revenue: $2.8 million from Gilead collaboration. 
- R&D expenses: $74.1 million (cash-adjusted: $57 million), down 7% sequentially. 
- G&A expenses: $17.3 million (cash-adjusted: $9.9 million), down 3% sequentially. 
- Cash balance: $978.7 million, providing runway into H2 2028. 
- Milestone potential: $85 million from Gilead collaboration, with $42.5 million received to date.

**【Q&A Highlights】**
- **KT-621 Efficacy**: CEO emphasized dupilumab-like TARC reduction (70-80%) in AD patients, with Phase Ib data expected in December. 
- **Trial Design**: Phase IIb AD trial (BROADEN2) will evaluate 3 doses, powered for EASI-50 and Pruritus NRS endpoints. 
- **Competitive Landscape**: KT-621's oral, once-daily dosing differentiates from biologics; no direct competitors in STAT6 degrader space. 
- **Pipeline Expansion**: IRF5 program (KT-579) IND-enabling studies complete, with Phase I healthy volunteer study planned for early 2026. 
- **Capital Allocation**: CEO prioritizes KT-621 development while maintaining balance with pipeline expansion, driven by data success.

Kymera Therapeutics, Inc. (KYMR) Q3 2025 Earnings Call Transcript

- **KT-621 STAT6 degrader**: Phase I data shows >95% STAT6 degradation at low doses; Q4 2025 AD Phase Ib readout to evaluate 2 doses.
- **Pipeline Expansion**: IRF5 degrader (KT-579) advancing to Phase I; CDK2 partnership with Gilead ($85M upfront, $750M total potential).
- **Financial Strength**: $1B cash balance post-Q2 2025; collaborations provide up to $1.725B in potential milestones.
- **Clinical Momentum**: Phase IIb AD and asthma trials set to start in Q4 2025 and Q1 2026, respectively.
- **Strategic Differentiation**: Oral STAT6 degrader with biologics-like efficacy; CDK2 degrader achieves >99% selectivity vs. CDK1.


**【CEO Summary Section】**
- Kymera achieved significant progress in 2025, including positive Phase I results for KT-621 (STAT6 degrader) in healthy volunteers, with >95% STAT6 degradation at low doses and no safety signals.
- Phase Ib trial in moderate-to-severe AD patients (n=20) is on track for Q4 2025 readout, evaluating 2 doses to assess biomarker and clinical endpoint translation.
- Finalized 3 doses for upcoming Phase IIb studies in AD and asthma, with IND-ready follow-on STAT6 degrader for future advancement.
- Expanded immunology pipeline with IRF5 degrader (KT-579) progressing to IND-enabling studies, targeting autoimmune diseases like lupus and RA.
- Strategic collaborations: Gilead partnership for CDK2 degrader (upfront $85M, $750M total potential) and Sanofi's opt-in for KT-485 IRAK4 degrader (up to $975M milestones).
- Extended cash runway to H2 2028 with $288M follow-on offering and $1B cash balance as of July 2025.

**【CFO Financial Commentary】**
- Q2 2025 revenue: $11.5M (all from Sanofi collaboration).
- Operating expenses: R&D $78.4M (adjusted $70.4M), G&A $17.6M (adjusted $10.2M), total adjusted OpEx down slightly QoQ.
- Cash balance: $963M as of June 30, increasing to $1B post-July proceeds from follow-on offering and Gilead upfront payment.
- Collaboration milestones: Up to $750M from Gilead (including $85M upfront) and $975M from Sanofi for KT-485.

**【Q&A Highlights】**
- **Dose Selection for Phase IIb**: Finalized 3 doses based on Phase I data; Q4 2025 AD trial will evaluate maximal vs. submaximal degradation profiles.
- **Safety Profile**: KT-621 showed no safety signals in healthy volunteers or GLP tox studies; Phase Ib will assess 4-week safety in AD patients.
- **Enrollment Success**: Rapid enrollment in Phase Ib driven by demand for oral STAT6 degrader; no placebo arm due to patient preference for active drug.
- **CDK2 Differentiation**: Molecular glue degrader achieves >99% CDK2 selectivity vs. CDK1, with potential for CNS penetration.
- **IRAK4 Update**: Sanofi prioritized KT-485 over KT-474 due to improved potency and profile; AstraZeneca's IRAK4 trial in COPD highlights indication potential.
- **IRF5 Progress**: KT-579 progressing to Phase I with IND filing expected in early 2026.


Kymera Therapeutics, Inc. (KYMR) Q2 2025 Earnings Call Transcript

- **$775M Cash Runway Extended to 2028**: Strategic resource allocation prioritizes STAT6 and IRF5 programs over TYK2. 
- **STAT6 Program (KT-621) Advancing Rapidly**: Phase 1a data (June 2025), Phase 2b trials in AD/asthma (Q4 2025/Q1 2026). 
- **IRF5 Program (KT-579) Shows Breakthrough Potential**: Lupus model efficacy superior to efamitrin, 100% survival in MRL-LPR mice. 
- **TYK2 Program Halted**: Redirected resources to address larger markets with unmet need. 
- **IRF5 Safety Profile**: Cell-specific degradation avoids broad immunosuppression, preserves antiviral responses. 


**【CEO Strategy Overview】**
- Kymera focuses on oral protein degraders targeting undrugged transcription factors in immunology, with a pipeline including STAT6 (KT-621), IRF5 (KT-579), and IRAK4 (KT-474). 
- The company has $775M in cash, extending runway to H1 2028, enabling strategic prioritization of high-impact programs.
- Decision to halt TYK2 (KT-295) development to allocate resources to STAT6 and IRF5 programs, which address larger patient populations with unmet need.

**【STAT6 Program Update】**
- KT-621: First-in-class oral STAT6 degrader targeting IL-4/13 pathway in Th2 diseases. 
- Upcoming milestones: Phase 1a data (June 2025), Phase 1b AD study (Q4 2025), Phase 2b trials in AD and asthma (Q4 2025/Q1 2026). 
- Preclinical data shows dupilumab-like efficacy in asthma and AD models with 90%+ STAT6 degradation. 

**【IRF5 Program Introduction】**
- KT-579: First-in-class oral IRF5 degrader targeting type 1 interferon and pro-inflammatory cytokines in autoimmune diseases. 
- Preclinical highlights: 
  - 90%+ IRF5 degradation in human primary cells (B cells, dendritic cells) with no off-target effects. 
  - Superior efficacy vs. efamitrin and deucravacitinib in lupus models, with 100% survival in MRL-LPR mice. 
  - Well-tolerated in NHP with no adverse effects at 200x therapeutic dose. 
- Development timeline: IND filing (Q4 2025), Phase 1 start (Q1 2026). 

**【Resource Allocation & Risk Management】**
-Paused TYK2 program due to competitive landscape and prioritization of STAT6/IRF5 with larger market opportunities. 
- IRAK4 collaboration with Sanofi progressing in hidradenitis suppurativa and AD Phase 2b studies (H1 2026 readouts). 
- $20M milestone payment from Sanofi for achieving IRAK4 preclinical milestones. 

**【Q&A Key Takeaways】**
- STAT6 degradation >90% in blood/skin needed for efficacy, supported by dupilumab-like preclinical data. 
- IRF5 safety profile benefits from cell-specific expression (dendritic cells, macrophages) and no impact on IRF3/7-mediated antiviral responses. 
- IRF5 potential to address lupus, RA, IBD with superior efficacy to B-cell depleters via multi-cytokine inhibition. 
- No feedback loop activation observed in long-term preclinical studies. 


Kymera Therapeutics (KYMR)-9 May 25-2025 Q1 Earnings call transcript

- **STAT6 Program Advancement**: Phase I healthy volunteer data expected June 2025; Phase IIb trials in AD and asthma starting late 2025/early 2026. 
- **TYK2 Program Initiation**: Phase I healthy volunteer study begins Q2 2025, targeting full TYK2 degradation. 
- **Financial Strength**: $851M cash runway into mid-2027, supporting multi-program clinical development. 
- **Innovation Focus**: Unveiling new immunology target in May 2025, maintaining 1 IND/year pipeline cadence. 
- **Biomarker Strategy**: 28-day Phase 1b AD trial designed to replicate dupilumab's Th2 biomarker profile.

**【CEO Summary Section】**
- Kymera Therapeutics focused on immunology, advancing STAT6 (KT-621) and TYK2 (KT-295) programs. STAT6 is first-in-class oral degrader targeting Th2 inflammation; TYK2 aims for IL-23/Type 1 interferon pathways. 
- 2024 achievements: IND filing for KT-621, Phase I healthy volunteer study completion, and expansion of Sanofi's IRAK4 Phase II trials. 
- 2025 milestones: Phase I data for KT-621 (June 2025), Phase IIb trials in AD and asthma, and TYK2 Phase I start in Q2 2025. New immunology target to be unveiled in May 2025.

**【CMO Clinical Update】**
- STAT6 program: Phase I healthy volunteer study (120 subjects) evaluating 90%+ STAT6 degradation in blood/skin. Phase Ib AD trial (20 patients, 28 days) to assess Th2 biomarkers (TARC, IgE) and clinical endpoints (EASI, pruritus). Phase IIb trials in AD (Q4 2025) and asthma (Q1 2026) for dose selection. 
- TYK2 program: KT-295 Phase I healthy volunteer study (Q2 2025) to demonstrate full TYK2 degradation. Phase II proof-of-concept planned in psoriasis. 
- IRAK4 program: Sanofi expanding Phase II trials in HS and AD, with mid-2026 primary completion dates.

**【CFO Financial Commentary】**
- Q4 2024 revenue: $7.4M (all from Sanofi collaboration). R&D expenses: $71.8M (includes $6.8M non-cash stock comp). G&A: $16.3M (includes $7M non-cash stock comp). 
- Cash balance: $851M at year-end, providing runway into mid-2027. Sufficient liquidity to fund Phase II trials across pipeline.

**【Q&A Highlights】**
- Phase 1b AD trial rationale: 28-day dosing sufficient to show biomarker changes (dupilumab-like effect), no placebo needed due to low biomarker variability. 
- Dose selection: Phase I healthy volunteer data will inform Phase IIb dose range. Preclinical data shows consistent tissue penetration across species. 
- TYK2 strategy: Target biologics-like activity in psoriasis with Phase II proof-of-concept. 
- Partnership approach: No plans to partner immunology programs; oncology programs advanced only in collaboration.

Actual	-0.29	-0.29	-0.55	-0.56	-0.66	-0.71	-0.78	-0.79	-0.6	-0.7	-0.67	-0.9	-0.25	-0.69	-0.58	-0.82	-0.88	-0.82	-0.95	-0.94	-0.97
Forecast	-0.0517	-0.1483	-0.2591	-0.3674	-0.4666	-0.6683	-0.6869	-0.7598	-0.6304	-0.6836	-0.6356	-0.6368	-0.4035	-0.7206	-0.6813	-0.8323	-0.7748	-0.907	-0.81	-0.7697	-0.7837
Surprise	-460.93%	-95.55%	-112.27%	-52.42%	-41.45%	-6.24%	-13.55%	-3.97%	+4.82%	-2.40%	-5.41%	-41.33%	+38.04%	+4.25%	+14.87%	+1.48%	-13.58%	+9.59%	-17.28%	-22.13%	-23.77%

KYMR

KYMR fundamentals

KYMR Q4 2025 Earnings

Earnings Call

You can ask Aime

KYMR

KYMR fundamentals

KYMR Q4 2025 Earnings

Earnings Call

KYMR Earnings Call Summary for Q4/20258:30 AM on Feb 26, 2026

KYMR Earnings Call Summary for Q3/20258:30 AM on Nov 4, 2025

KYMR Earnings Call Summary for Q2/20258:30 AM on Aug 11, 2025

KYMR Earnings Call Summary for Q1/202510:00 AM on May 9, 2025

KYMR Earnings Call Summary for Q4/20248:30 AM on Feb 27, 2025

You can ask Aime